



Curriculum Vitae

Personal information **Alexandros Mathioudakis**

Work experience

07/2025 - current:

--- Senior Lecturer in Respiratory Medicine, The University of Manchester, UK &

--- Honorary Consultant Respiratory Physician, Manchester University NHS Foundation Trust, UK

50% of my time is committed to direct care of patients with respiratory conditions. The remaining 50% of my time is committed to clinical research with a focus on airway diseases characterisation and precision medicine therapeutic approaches, as well as on the methodology of clinical research and evidence synthesis. I also contribute to undergraduate, postgraduate and continuous medical education training.

06/2025 - 07/2025:

--- Locum Consultant Respiratory Physician and Pickering Fellow, Manchester University NHS Foundation Trust, UK.

As above.

02/2022 - 05/2025:

--- NIHR Clinical Lecturer in Respiratory Medicine & Specialty Trainee in Respiratory and General Internal Medicine, The University of Manchester, UK

50% of my time was committed to clinical training in respiratory and general internal medicine and direct care of patients with respiratory or acute medical conditions. The remaining 50% of my time was committed to research and teaching, as previously described.

08/2018 - 01/2022:

--- Clinical Research Fellow in Respiratory Medicine, Manchester University NHS Foundation Trust,

--- PhD student, The University of Manchester.

I completed my PhD, while in parallel contributing to a COPD outpatient clinic.

08/2016 - 07/2018:

--- Academic Clinical Fellow in Respiratory Medicine & Specialty Trainee in Respiratory and General Internal Medicine, Health Education North West

75% of my time was committed to clinical training in respiratory and general internal medicine and direct care of patients with respiratory or acute medical conditions. The remaining 25% of my time was committed to research and teaching, as previously described.

02/2016 - 07/2016

--- European Respiratory Society Guidelines Methodology Fellowship.

Rigorous training and hands-on experience in the design and conduct of systematic reviews, meta-analyses and clinical practice guidelines. This fellowship included a 3-month placement in Cochrane Iberoamerica, Barcelona, Spain, and a 3-month placement in the National Institute of Health and Care Excellence (NICE), Manchester, UK.

08/2013 - 01/2016

--- Core Medical Trainee, Health Education North West.

Clinical training in acute and general internal medicine.

08/2012 - 07/2013

--- Foundation Year 2 Trainee, Health Education North West.

Clinical training in acute and general internal medicine.

08/2012 - 05/2025: **MRCP(Respiratory); Completion of clinical training in Respiratory and General Internal Medicine, Health Education North West, UK.**

08/2022 - 10/2024: **FHEA; Fellow of the Higher Education Academy (AdvanceHE), UK.** Awarded following completion of the New Academics Programme at the University of Manchester and submission of a portfolio demonstrating my experience, commitment and excellence in teaching and my strong grounding in pedagogic theory.

08/2018 - 02/2022: **PhD in Respiratory Medicine, The University of Manchester, UK.** Dissertation title: Methodology and feasibility of randomised controlled trials evaluating precision medicine interventions for acute exacerbations of chronic obstructive pulmonary disease (COPD).

09/2005 - 10/2011: **MD; Degree in Medicine, National and Kapodistrian University of Athens, Greece.**

Additional information

Publications

I have published >150 peer reviewed papers indexed in PubMed, including 62 publications as the first, last or corresponding author. My h-index is 47 and my i-10 index is 112, based on >18,000 citations according to Google Scholar, while my total impact factor exceeds 3,800 (mean impact factor: 24.3).

Guidelines – Official Statements

A1. Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, **Mathioudakis AG**, Briel M, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, Neumann I, Kahale LA, Iorio A, Meerpohl J, Schünemann HJ, Akl EA. [GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence.](#) *J Clin Epidemiol* 2017; 87:14-22.

A2. SIGN/BTS. [British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society & Scottish Intercollegiate Guidelines Network \(BTS/SIGN\).](#) 2019.

A3. Akl E, Morgan R, Rooney A, Beverly B, Katikireddi S, Agarwal A, Alper B, Alva Diaz C, Amato L, Ansari M, Brozek J, Chu D, Dahm P, Darzi A, Falavigna M, Gartlehner G, Pardo-Hernandez H, King V, Klugarova J, Langendam M, Lockwood C, Mammen M, **Mathioudakis AG**, McCaul M, Meerpohl J, Minozzi S, Mustafa R, Nonino F, Piggot G, Qaseem A, Riva J, Rodin R, Sekercioglu N, Skoetz N, Traversy G, Thayer K, Schunemann H. [Developing trustworthy recommendations as part of an urgent response \(1-2 weeks\): A GRADE concept paper.](#) *J Clin Epidemiol* 2021; 129:1-11.

A4. Brozek JL, Canelo Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, Cronin M, Djulbegovic B, Falavigna M, Guyatt GH, Gordon AA, Hilton Boon M, Hutubessy RCW, Joore MA, Katikireddi V, LaKind J, Langendam M, Manja V, Magnuson K, **Mathioudakis AG**, Meerpohl J, Mertz D, Mezencev R, Morgan R, Morgano GP, Mustafa R, O'Flaherty M, Patlewicz G, Riva JJ, Posso M, Rooney A, Schloesser PM, Schwartz L, Shemilt I, Tarride JE, Thayer KA, Tsaounis K, Vale L, Wambaug J, Wignall J, Williams A, Xie F, Zhang Y, Schunemann HJ, for the GRADE Working Group. [GRADE Guidelines 30: The GRADE approach to assessing the certainty of modelled evidence - an overview in the context of health decision making.](#) *J Clin Epidemiol.* 2021; 129:138-150

****A5. Mathioudakis AG**, Tsilochristou O, Adcock IM, Bikov A, Bjermer L, Clini E, Flood B, Herth F, Horvath I, Kalayci O, Papadopoulos NG, Ryan D, Sanchez Garcia S, Correia-de-Sousa J, Tonia T, Pinnock H, Agache I, Janson C. [ERS/EAAACI statement on adherence to international adult asthma guidelines.](#) *Eur Respir Rev* 2021; 30(161):210132.

A6. Baughman RP, Valeyre D, Korsten P, **Mathioudakis AG**, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou KM, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. [ERS Clinical Practice Guidelines on Treatment of Sarcoidosis.](#) *Eur Respir J* 2021; 58(6):2004079.

****A7. Mathioudakis AG**, Abroug F, Agusti A, Ananth S, Bakke P, Bartzokas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner GJ, Csoma B, Emelyanov A, Faner R, Fernandez-Romero G, Hammouda Z, Horváth P, Huerta Garcia A, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, Linnell J, López-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen JU, on behalf of the DECODE-NET. [ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease \(COPD\) exacerbations.](#) *Eur Respir J* 2022; 59(5):2102006.

A8. Schünemann HJ, Neumann I, Hultcrantz M, Brignardello-Petersen R, Zeng L, Murad MH, Izcovich A, Morgano GP, Baldeh T, Santesso N, Cuello CG, Mbuagbaw L, Guyatt G, Wiercioch W, Piggott T, De Beer H, Vincet M, **Mathioudakis AG**, Mayer MG, Mustafa R, Filippini T, Iorio A, Nieuwlaat R, Marcucci M, Alonso Coello P, Bonovas S, Piovani D, Tomlinson G, Akl EA. [GRADE Guidance 35: Update on rating imprecision for assessing contextualized certainty of evidence and making decisions.](#) *J Clin Epidemiol* 2022; 150:225-242.

A9. Humbert M, Kovacs G, Hoepfer MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; **ESC/ERS Scientific Document Group.** [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.](#) *Eur Respir J* 2023; 61(1):2200879.

A10. Humbert M, Kovacs G, Hoepfer MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; **ESC/ERS Scientific Document Group.** [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.](#) *Eur Heart J* 2022; 43(88):3618-3731

A11. Papadopoulos N, Custovic A, Deschildre A, Gern J, Nieto-Garcia A, Miligkos M, Phipatanakul W, Xepapadaki P, Agache I, Arasi S, Awad Z, Bacharier L, Bonini M, Braidó F, Caimmi D, Castro-Rodriguez J, Chen Z, Clausen M, Craig T, Diamant Z, Ducharme F, Ebisawa M, Eigenmann P, Feleszko W, Fierro V, Flocchi A, Garcia-Marcos L, Goh A, Gomez M, Gotua M, Hamelmann E, Hedlin G, Hossny E, Ispayeva Z, Jackson D, Jartti T, Jesenak M, Kalayci O, Kaplan A, Konradsen J, Kuna P, Lau S, LeSouéf P, Lemanske R, Levin M, Makela M, **Mathioudakis AG**, Mazulov O, Morais-Almeida M, Murray C, Novák Z, Pawankar R, Pijnenburg M, Pite H, Pitrez P, Pohunek P, Price D, Priftanji A, Ramiconi V, Yeverino DR, Roberts G, Sheikh A, Shen K, Szepefalusi Z, Tsiligianni I, Turkalj M, Turner S, Umanets T, Valiulis A, Vijveberg S, Wang J, Winders T, Yon DK, Osman Y, Zar H. [Recommendations for asthma monitoring in children. A PeAIRL document endorsed by APAPAIRL, EAACI, INTERASMA, REG & WAO.](#) *Pediatric Allergy and Immunology* 2024; 35(4):e14129.

****A12.** McCarthy C, Bonella F, O'Callaghan M, Dupin C, Alfaro T, Fally M, Borie R, Campo I, Cottin V, Fabre A, Griese M, Hadchouel A, Jouneau S, Kokosi M, Manali E, Prosch H, Trapnell B, Veltkamp M, Wang T, Toews

I, **Mathioudakis AG***, Bendstrup E*. (**shared senior authorship**). [European Respiratory Society Guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis](#). *Eur Respir J* 2024. In press.

A13. Klugar M, Lofti T, Darzi AJ, Reinap M, Klugarova J, Kantorova L, Xia J, Brignardello-Petersen R, Pokorna A, Hazlewood G, Munn Z, Morgan RL, Toews I, Neumann I, Bhatarakoon P, Stein AT, McCaul M, **Mathioudakis AG**, D'Ani KE, Leontaridis GI, Naude C, Vasanthan LT, Khabisa J, Malgorzata MB, Mustafa R, DiValerio Gibbs K, Nieuwlaar R, Santesso N, Pieper D, Mokrane S, Soghier I, Lertwattananawit W, Wiercioch W, Sultan S, Rozmarinova J, Drapacova P, Song Y, Amer M, Amer YS, Sayfi S, Verstijnen IM, Shin ES, Saz-Parkinson Z, Pottie K, Ruspi A, Marusic A, Saif-Ur-Rahman KM, Rojas MX, Akl EA, Schunemann HJ, for the GRADE Working Group. [GRADE Guidance 39: Using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses](#). *J Clin Epidemiol* 2024. In press.

Original research studies:

****B1. Mathioudakis AG**, Amanetopoulou SG, Gialmanidis I, Chatzimavridou-Grigoriadou V, Siasos G, Evangelopoulou E, Mathioudakis GA. [Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of COPD patients: Aggravating or Beneficial?](#) *Respirology* 2013; 18(1):147-53.

B2. Gialmanidis IP, Bravou V, Petrou I, Kourea H, **Mathioudakis AG**, Lilis I, Papadaki H. [Expression of BMI1, FoxF1, Nanog and \$\gamma\$ -Catenin in relation to Hedgehog Signaling Pathway in Human Non-Small-Cell Lung Cancer](#). *Lung* 2013; 191(5):511-21.

B3. Mathioudakis AG, Kanavidis P, Chatzimavridou-Grigoriadou V, Gialmanidis I, Amanetopoulou SG, Christophoulou E, Evangelopoulou E, Mathioudakis GA. [Tiotropium Improves the Survival of COPD Patients: A Systematic Review and Meta-Analysis](#). *J Aerosol Med Pulm Drug Deliv* 2014; 27(1): 43-50.

B4. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis GA, Siafakas NM. [Comparative Mortality Risk of Tiotropium Administered via Handihaler or Respimat in COPD Patients: Are they Equivalent?](#) *Pulm Pharmacol Ther* 2014; 28(2):91-97.

B5. Barouchos N, Papazafiropoulou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, **Mathioudakis AG**, Christophoulou E, Kolstida S, Bassiakou E. [Comparison of Tumor Markers and Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease Exacerbations](#). *Scan J Clin Lab Invest* 2015; 75(2):126-32.

B6. Martinez-Zapata M, **Mathioudakis AG**, Mousa S, Bauersachs R. [Tinzaparin for long-term treatment of venous thromboembolism in patients with cancer: A systematic review and meta-analysis](#). *Clin Appl Thromb Hemost* 2017; 1:1076029617696581.

B7. Miravittles M, Urrutia G, **Mathioudakis AG**, Ancochea J. [Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis](#). *Resp Res* 2017;18(1):196.

B8. Donovan T, Felix LM, Chalmers JD, Milan SJ, **Mathioudakis AG**, Spencer S. [Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis](#). *Protocol*. *Cochrane Database Syst Rev* 2017;7:CD012733.

****B9.** Normansell R, Kew K, **Mathioudakis AG**. [Interventions to improve inhaler technique for people with asthma](#). *Cochrane Database Syst Rev* 2017;3:CD012286.

****B10. Mathioudakis AG**, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. [Procalcitonin to guide antibiotic administration in COPD exacerbations: A meta-analysis](#). *Eur Respir Rev* 2017;26(143). Pii: 160073.

B11. Janjua S, Dias S, Threapleton CJD, **Mathioudakis AG**, Normansell R. [Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis \(Protocol\)](#). *Cochrane Database Syst Rev* 2018. 11:CD013198.

B12. Donovan T, Felix LM, Chalmers JD, Milan SJ, **Mathioudakis AG**, Spencer S. [Continuous versus intermittent antibiotics for bronchiectasis](#). *Cochrane Database Syst Rev* 2018;6:CD012733.

B13. Mathioudakis AG, Janjua S, Normansell R, Vestbo J. [Biomarkers to guide antibiotic therapy for COPD Exacerbations \(Protocol\)](#). *Cochrane Database Syst Rev* 2018;10:CD013148.

B14. Gayle A, Dickinson S, Morris K, Poole C, **Mathioudakis AG**, Vestbo J. [What is the impact of the GOLD 2017 recommendations in primary care? A descriptive study of patient classifications, treatment burden and costs](#). *Int J Chron Obstruct Pulmon Dis* 2018; 13:3485-92.

B15. Mathioudakis AG, Salakari M, Pylkkanen L, Saz-Parkinson Z, Bramesfeld A, Deandrea S, Lerda D, Neamtiiu L, Pardo-Hernandez H, Solà I, Alonso-Coello P. [Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services](#). *Psycho-Oncology* 2019;28(5):939-47.

B16. Ahmadpour E, Foroutan-Rad M, Majidiani H, Moghaddam SM, Hatam-Nahavandi K, Hosseini SA, Rahimi MT, Barac A, Rubino S, Zarean M, **Mathioudakis AG**, Cevik M. [Transfusion-transmitted Malaria: A Systematic Review and Meta-Analysis](#). *Open Forum Infectious Diseases* 2019; ofz283.

B17. Barac A, Karimzadeh-Esfahani H, Pourostadi M, Taghi Rahimi M, Ahmadpour E, Rashedi J, Mahdaviopour B, Kafili HS, Spotin A, Abate KH, **Mathioudakis AG (corresponding)**, Asgharzadeh M. [Laboratory cross-contamination of Mycobacterium tuberculosis: a systematic review and meta-analysis](#). *Lung* 2019;197(5):651-661.

B18. Spencer S, Donovan T, Chalmers JD, **Mathioudakis AG**, McDonnell MJ, Tsang A, Pilkington G. [Intermittent prophylactic antibiotics for bronchiectasis \(Protocol\)](#). *Cochrane Database Syst Rev* 2019; 11: CD013254.

B19. Mathioudakis AG, Janner J, Moberg M, Alonso-Coello P, Vestbo J. [A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomized controlled trials on the management of COPD exacerbations](#). *ERJ Open Research*. 2019; 5(4):00136-2019.

B20. Mathioudakis AG, Moberg M, Janner J, Alonso-Coello P, Vestbo J. [Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials](#). *ERJ Open Research* 2019; 5:00072-2019.

B21. Kantarakia C, Tsoumani ME, Galanos A, **Mathioudakis AG**, Giannoulaki E, Beloukas A, Voyiatzaki C. [Comparison of the Level of Awareness about the Transmission of Echinococcosis and Toxocariasis between Pet Owners and Non-Pet Owners in Greece](#). *Int J Environ Res Public Health* 2020; 17:E5292.

B22. Mann ER, Mennon M, Knight SB, Konkel JE, Jagger C, Shaw TN, Krishnan S, Rattray M, Ustianowski A, Bakerly ND, Dark P, Lord G, Simpson A, Felton T, Ho LP, NIHR Respiratory TRC, Feldmann M, **CIRCO**, Grainger J, Hussell T. [Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19](#). *Sci Immunol* 2020; 5(51):eabd6197.

B23. Papadopoulos NG, Custovic A, Deschildre A, **Mathioudakis AG**, Phipatanakul W, Wong G, Xepapadaki P, Agache I, Bacharier L, Bonini M, Castro-Rodriguez JA, Chen Z, Craig T, Ducharme FM, El-Sayeb ZA, Feleszko W, Fiocchi A, Garcia-Marcos L, Gern GE, Goh A, Gomez RM, Hamelmann EH, Hedlin G, Hossny EM, Jartti T, Kalayci O, Kaplan A, Konradsen J, Kuna P, Lau S, Le Souef P, Lemanske RF, Makela MJ, Morais-Almeida M, Murray C, Nagaraju

K, Namazova-Baranova L, Garcia AN, Osman Y, Pitrez PMC, Pohunek P, Beltran CFP, Roberts GC, Valiulis A, Zar HJ, PeARL collaborators. [Impact of COVID-19 on pediatric asthma: Practice adjustments and disease burden](#). **JACI: In Practice** 2020; 8(8):2592-2599.e3

****B24. Mathioudakis AG**, Custovic A, Deschildre A, Ducharme FM, Kalayci O, Murray C, Garcia AN, Phipatanakul W, Price D, Sheikh A, Agache I, Bacharier L, Bonini M, Castro-Rodriguez JA, De Carlo G, Craig T, Diamant J, Feleszko W, Ierodiakonou D, Gern JE, Grigg J, Hedlin G, Hossny EM, Jartti T, Kaplan A, Lemanske RF, Le Souef P, Makela MJ, Matricardi PM, Miligkos M, Morais-Almeida M, Pite H, Pitrez PMC, Pohunek P, Roberts G, Sanchez-Garcia S, Tsiligianni I, Turner S, Winders TA, Wong G, Xepapadaki P, Zar HJ, Papadopoulos NG. [Research priorities in pediatric asthma: Results of a global survey of multiple stakeholder groups by the Pediatric Asthma in Real Life \(PeARL\) think Tank](#). **JACI: In Practice** 2020; 8(6):1953-1960.e9.

B25. Sivapalan P, Jørgensen NR, **Mathioudakis AG**, Eklöf J, Lapperre T, Suppli Ulrik C, Andreassen HF, Armbruster K, Sivapalan P, Janner J, Godtfredsen N, Weinreich UM, Nielsen TL, Seersholm N, Wilcke T, Schuetz P, Klausen TW, Marså K, Vestbo J, Jensen JU. [Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial](#). **Respir Res** 2020; 21(1):263.

B26. Mathioudakis AG, Abroug F, Agusti A, Bakke P, Bartzioakas K, Beghe B, Bikov A, Bradbury T, Brusselle G, Cadus C, Coleman C, Contoli M, Corlateanu A, Corlateanu O, Criner G, Csoma B, Emlayanov A, Faner R, Fernandez-Romero G, Hammouda Z, Horvath P, Huerta Garcia A, Jacobs M, Jenkins C, Joos G, Kharevich O, Kostikas K, Lapteva E, Lazar Z, Leuppi JD, Liddle C, Lopez-Giraldo A, McDonald VM, Nielsen R, Papi A, Saraiva I, Sergeeva G, Sioutkou A, Sivapalan P, Stovold E, Wang H, Wen F, Yorke J, Williamson PR, Vestbo J, Jensen J-U. [Core Outcome Set for the management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The COS-AECOPD ERS Task Force study protocol](#). **ERJ Open Res** 2020; 6(3):00193-2020.

B27. Kefala AM, Fortescue R, Alimani GS, Kanavidis P, McDonnell MJ, Magiorkinis E, Megremis S, Paraskevis D, Voyiatzaki C, Mathioudakis GA, Papageorgiou E, Papadopoulos NG, Vestbo J, Beloukas A, **Mathioudakis AG**. [Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease \(COPD\) and exacerbations: A systematic review and meta-analysis protocol](#). **BMJ Open** 2020; 10(4): e035640.

B28. Mathioudakis AG, Fally M, Hashad R, Kouta A, Hadi AS, Knight SB, Bakerly ND, Singh D, Williamson P, Felton T, Vestbo J. [Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic review](#). **Life (Basel)** 2020; 10(12):350.

****B29. Mathioudakis AG**, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, Vestbo J. [Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical responses in COPD](#). **Eur Respir J** 2020; 55(5):1902119.

B30. Kosmidis C, Hashad R, **Mathioudakis AG**, McCahery T, Richardson MD, Vestbo J. [Impact of self-reported environmental mould exposure on COPD outcomes](#). **Pulmonology** 2021; S2531-0437(21)00096-9.

B31. Shuwa HA, Shaw TN, Knight SB, Wemyss K, McClure FA, Pearmain L, Prise I, Jagger C, Morgan DJ, Khan S, Brand O, Mann ER, Ustianowski A, Bakerly ND, Dark P, Brightling CE, Brij S, **CIRCO**, Felton T, Simpson A, Grainger JR, Hussell T, Konkel JE, Menon M. [Alterations in T and B cell function persist in convalescent COVID-19 patients](#). **Med (N Y)** 2021; 2(6):720-735.e4.

B32. Meszaros M, **Mathioudakis AG**, Xanthoudaki M, Sircu V, Nena E, Vestbo J, Corlateanu A, Steiroopoulos P, Bikov A. [The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea](#). **Sleep Biol Rhythms**. 2021; 19:399-408.

B33. Bikov A, Frenst S, Meszaros M, Kunos L, **Mathioudakis AG**, Negru GA, Gaita L, Mihaicuta S. [Triglyceride-glucose index in non-diabetic, non-obese patients with obstructive sleep apnoea](#). **J Clin Med** 2021; 10(9):1932.

B34. Sivapalan P, Bikov A, Suppli-Ulrik C, Lapperre TS, **Mathioudakis AG**, Højberg Lassen MC, Skaarup KG, Biering-Sørensen T, Vestbo J, Jensen JUS. [Corticosteroid resistance in smokers – a sub study analysis of the CORTICO-COP randomised controlled trial](#). **J Clin Med** 2021; 10(12):2734.

B35. Mathioudakis AG, Miligkos M, Boccabella C, Alimani GS, Custovic A, Deschildre A, Ducharme FM, Kalayci O, Murray C, Garcia AN, Phipatanakul W, Price D, Sheikh A, Agache I, Bacharier L, Beloukas A, Bentley A, Bonini M, Castro-Rodriguez JA, De Carlo G, Craig T, Diamant J, Feleszko W, Felton T, Gern JE, Grigg J, Hedlin G, Hossny EM, Ierodiakonou D, Jartti T, Kaplan A, Lemanske RF, Le Souef P, Makela MJ, Mathioudakis GA, Matricardi PM, Mitrogiorgou M, Morais-Almeida M, Nagaraju K, Papageorgiou E, Pite H, Pitrez PMC, Pohunek P, Roberts G, Tsiligianni I, Turner S, Vijverberg S, Winders TA, Wong G, Xepapadaki P, Zar HJ, Papadopoulos NG. [Management of Asthma in Childhood: Study Protocol of a Systematic Evidence Update by the Pediatric Asthma in Real Life \(PeARL\) Think Tank](#). **BMJ Open** 2021; 11(7):e048338.

B36. Sivapalan P, Rutishauser J, Suppli-Ulrik C, Leuppi JD, Pedersen L, Mueller B, Eklöf J, Biering-Sørensen T, Gottlieb V, Armbruster K, Janner J, Moberg M, Lapperre TS, Nielsen TL, Browatzki AL, **Mathioudakis AG**, Vestbo J, Schuetz P, Jensen JUS. [Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials](#). **Respir Res** 2021; 22(1):155.

B37. Janjua S, **Mathioudakis AG**, Fortescue R, Walker RAE, Sharif S, Threapleton CJD, Dias S. [Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis](#). **Cochrane Database Syst Rev** 2021; 1:CD013198.

B38. Papadopoulos NG, **Mathioudakis AG**, Custovic A, Deschildre A, Phipatanakul W, Wong G, Xepapadaki X, Abou-Taam R, Agache I, Castro-Rodriguez JA, Chen Z, Cros P, Dubus JC, El-Sayed ZA, El-Owaidy R, Feleszko W, Fierro V, Fiocchi A, Garcia-Marcos L, Goh A, Hossny EM, Huerta Villalobos YR, Jartti T, Le Roux P, Levina J, López García AI, Ramos AM, Morais-Almeida M, Murray C, Nagaraju K, Nagaraju MK, Navarrete Rodriguez EM, Namazova-Baranova L, Nieto Garcia A, Pozo Beltrán CF, Ratchataswan T, Rivero Yeverino D, Rodriguez Zagal E, Schweitzer CE, Tulkki M, Wasilczuk K, XU D, PeARL collaborators, on behalf of the PeARL Think Tank. [Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort](#). **Allergy**. 2021; 76(6):1765-1775.

B39. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. [Self-reported real-world safety and reactogenicity of COVID-19 vaccines: A vaccine-recipient survey](#). **Life** 2021; 11(3):249.

B40. Lapteva EA, Kharevich ON, Khatsko VV, Voronova NA, Chamko MV, Bezruchko V, Katibnikova EI, Loban EI, Mouawie MM, Binetskaya H, Aleshkevich S, Karankevich A, Dubinetski V, Vestbo J, **Mathioudakis AG**. [Automated lung sound analysis using the LungPass platform: A sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19](#). **Eur Respir J** 2021; 58(6):2101907.

B41. RECOVERY Collaborative Group. [Colchicine in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial](#). **Lancet Respir Med** 2021; 9(12):1419-1426.

B42. Mathioudakis AG, Ananth S, Bradbury T, Csoma B, Sivapalan P, Stovold E, Fernandez-Romero G, Lazar Z, Criner GJ, Jenkins C, Papi A, Jensen JU, Vestbo J, on behalf of the DECODE-NET. [Assessing treatment success or failure as an outcome in randomised clinical trials of COPD exacerbations. A meta-epidemiological Study](#). **Biomedicines** 2021; 9(12):1837.

- B43.** Fally M, **Mathioudakis AG**, Wingfield-Digby J, Williamson PR. [Outcomes assessed in therapeutic randomised controlled trials in hospitalised patients with COVID-19: Is the meta Core Outcome Set \(meta-COS\) adopted?](#) *Clin Microbiol Infect* 2022; 28(3):456-457.
- B44. RECOVERY Collaborative Group.** [Aspirin in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) *Lancet* 2022; 399(10320):143-151.
- B45.** Papadimitriou E, Boutzios G, **Mathioudakis AG**, Vlahos NF, Vlachoyiannopoulos P, Mastorakos G. [Presence of antiphospholipid antibodies is associated with increased implantation failure following in vitro fertilization technique and embryo transfer: A systematic review and meta-analysis.](#) *Plos One* 2022; 17(7):e0260759.
- B46.** Spencer S, Donovan T, Chalmers JD, **Mathioudakis AG**, McDonnell MJ, Tsang A, Leadbetter P. [Intermittent prophylactic antibiotics for bronchiectasis.](#) *Cochrane Database Syst Rev* 2022; 1(1):CD013254.
- B47.** Wilson JC, Kealy D, James SR, Plowman T, Newling K, Jagger C, Filbey K, Mann ER, Konkel JE, Menon M, Knight SB, Simpson A, **CIRCO collaborative group**, Prihartadi A, Forshaw G, Todd N, Yates DRA, Grainger JR, Hussell T, Kaye PM, Signoret N, Lagos D. [Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19.](#) *iScience* 2022;25(1):103672.
- B48.** Sivapalan P, Borresen SW, Eklof J, Klose M, Holm FS, Feldt-Rasmussen U, Rossing M, Jorgensen NR, Marvig RL, Saeed MI, Wilcke T, Seersholm N, **Mathioudakis AG**, Vestbo J, Jensen JUS. [Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms.](#) *PLOS One*2022;17(2):e0262898.
- B49.** Armocida B, Monasta L, Sawyer S, Bustreo F, Segafredo G, Castelpietra G, Ronfani L, Pasovic M, Hay S, **GBD 2019 Europe NCDs in Adolescents Collaborators**, Perel P, Beran D. [Burden of non-communicable diseases among adolescents aged 10-24 years in the EU, 1990-2019: a systematic analysis of the Global Burden of Diseases Study 2019.](#) *Lancet Child Adolesc Health*2022; 6(6):367-383.
- B50. RECOVERY Collaborative Group.** [Casirivimab and imdevimab in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) *Lancet* 2022; 399(10325):665-676.
- B51.** Vardavas C, Nikitara K, **Mathioudakis AG**, Hilton-Boon M, Phalkey R, Leonardi-Bee J, Parris A, Deogan C, Suk JE. [Transmission of SARS-CoV-2 in educational settings in 2020: a review.](#) *BMJ Open* 2022; 12(4):e058308.
- B52. RECOVERY Collaborative Group.** [Baricitinib in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial and updated meta-analysis.](#) *Lancet* 2022; 400(10348):359-368.
- **B53.** Vardavas CI, **Mathioudakis AG**, Nikitara K, Stamatelopoulos K, Georgiopoulos G, Phalkey R, Leonardi-Bee J, Fernandez E, Carnicer-Pont D, Vestbo J, Semenza JC, Deogan C, Suk JE, Kramarz P, Lamb F, Penttinen P. [Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe.](#) *Eur Respir Rev*2022; 31(166):220098.
- B54.** Kamstrup P, Bülow Sand JM, Suppli Ulrik C, Janner J, Rønn CF, Rønnow SR, Leeming DJ, Jensen SG, Wilcke T, **Mathioudakis AG**, Miravittles M, Lapperre T, Bendstrup E, Frikke-Schmidt R, Murray DD, Itenov T, Bossios A, Nielsen SD, Vestbo J, Biering-Sorensen T, Karsdal M, Jensen JUS, Sivapalan P. [Biomarkers of clot activation and degradation and risk of future major cardiovascular events in acute exacerbation of COPD: A cohort sub-study in a randomised trial population.](#) *Biomedicines* 2022; 10(8):2011.
- B55. European Antimicrobial Resistance Collaborators.** [The burden of antimicrobial resistance in the WHO European Region 2019: a cross-country systematic analysis.](#) *Lancet Public Health* 2022; 7(11):e897-e913.
- B56.** Bampali M, Konstantinidis K, Kellis EE, Pouni T, Mitroulis I, Kottaridi C, **Mathioudakis AG**, Beloukas A, Karakalioti I. [West Nile disease symptoms and comorbidities: A systematic review and analysis of cases.](#) *Trop Med Infect Dis* 2022; 7(9):236.
- B57. GBD 2019 LRI Collaborators.** [Age-sex differences in the global burden of lower respiratory infections and risk factors: results from the Global Burden of Disease Study 2019.](#) *Lancet Infect Dis* 2022; 22(11):1626-1647.
- B58.** Kole TM, Vanden Berge E, Kraft M, Vonk JM, Nawijn MC, Siddiqui S, Sun K, Fabbri LM, Rabe KF, Chung KF, Nicolini G, Papi A, Brightling C, Singh D, van der Molen T, Dahlén SE, Agusti A, Faner R, Wiedzicha JA, Donaldson GC, Adcock IM, Lahousse L, Kerstjens HAM, van den Berge M; ATLANTIS; U-BIOPRED; **CADSET investigators.** [Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.](#) *Lancet Respir Med* 2023; 11(1):55-64.
- **B59.** Papadopoulou E, Hansel J, Lazar Z, Kostikas K, Tryfon S, Vestbo J, **Mathioudakis AG.** [Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: A meta-analysis.](#) *Eur Respir Rev* 2023; 32(167):220141.
- B60.** Heerfordt CK, Eklöf J, Sivapalan Ph, Ingebrigtsen TS, Biering-Sørensen T, Harboe ZB, Moberg M, Petersen JK, Andersen JO, Boel JB, Bock AK, **Mathioudakis AG**, Hurst JR, Kolekar S, Johansson SL, Bangsbo JM, Jarløv JO, Dessau R, Laursen CB, Perch M, Jensen JU. [Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus Pneumoniae Infection. A Multiregional Epidemiological Study.](#) *Int J Chron Obstruct Pulmon Dis* 2023; 18:373-384.
- B61. Recovery Collaborative Group.** [Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) *Lancet* 2023; 401(10387):1499-1507.
- B62.** Scott N, Pearmain L, Knight S, Brand O, Morgan D, Jagger C, Harbach S, Khan S, Ali Shuwa H, Franklin M, Kästele V, Williams T, Prise I, McClure F, Hackney P, Smith L, Menon M, Konkel J, Lawless C, Wilson J, **Mathioudakis AG**, Stanel S, Ustianowski A, Lindergard G, Brij S, Diar Bakerly N, Dark P, Brightling C, Rivera-Ortega P, Lord G, Horsley A, Piper Hanley K, Felton T, Simpson A, Grainger J, Hussell T, Mann, E. [Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID.](#) *Eur Respir J* 2023; 61(5):2202226.
- B63.** Papadopoulos NG, **Mathioudakis AG**, Custovic A, Deschildre A, Phipatanakul W, Wong G, Xepapadaki P, the PeARL Think Tank. [Current and optimal practices in childhood asthma monitoring among multiple international stakeholders.](#) *JAMA Netw Open*2023; 6(5):e2313120.
- B64. GBD 2019 IMID Collaborators.** [Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019.](#) *eClinicalMedicine* 2023; 64:102193.
- B65. RECOVERY Collaborative Group.** [Empagliflozin in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) *Lancet Diabetes Endocrinol* 2023; 11(12):905-914.
- B66. GBD 2019 Child and Adolescent Communicable Disease Collaborators.** [The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019.](#) *The Lancet* 2023; 402(10398):313-335.
- **B67. Mathioudakis AG**, Fally M, Hansel J, Robey RC, Haseeb F, Williams T, Kouta A, Welte T, Wootton DG, Clarke M, Waterer G, Dark P, Pneumonia Outcomes Group, Williamson PR, Vestbo J, Felton TW. [Clinical trials of](#)

[pneumonia management assess heterogeneous outcomes and measurement instruments.](#) **J Clin Epidemiol** 2023; 164:88-95.

B68. Alimani GS, Ananth S, Boccabella C, Khaleva E, Roberts G, Papadopoulos NG, Kosmidis C, Vestbo J, Papageorgiou E, Beloukas A, **Mathioudakis AG.** [Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis.](#) **PLOS One** 2023; 18(11):e0294416.

B69. Bennett MB, **Mathioudakis AG,** Wu J, Chu MMH, Tortini C, Thomas I, Simpson A. [Performance characteristics of basophil activation test for diagnosing penicillin allergy: a meta-analysis.](#) **J Allergy Clin Immunol Pract** 2024; 12(3):714-723.e5.

****B70.** Papadopoulou E, Bin Safar S, Khalil A, Hansel J, Wang R, Corlateanu A, Kostikas K, Tryfon S. Vestbo J, **Mathioudakis AG.** [Inhaled versus systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.](#) **Eur Respir Rev** 2024;33(171):230151.

B71. Papadopoulou E, Haidich A-B, **Mathioudakis AG,** Tsavlis D, Papadopoulou K, Oikonomidou R, Bogiatzidis P, Tryfon S. [The Fagerström Test for Nicotine Dependence, as a prognostic factor, in current smokers with and without COPD: a cross-sectional study in northern Greece.](#) **Chron Respir Dis** 2024; 21:14799731241235213.

B72. RECOVERY Collaborative Group. [Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 \(PIMS-TS, MIS-C: RECOVERY\): a randomised, controlled, open-label, platform trial.](#) **Lancet Child Adolesc Health** 2024; 8(3):190-200.

B73. RECOVERY Collaborative Group. Horby PW, Peto L, Staplin N, Campbell M, Pessoa-Amorim G, Mafham M, Emberson JR, Stewart R, Prudon B, Uriel A, Green CA, Dhasmana DJ, Malein F, Majumdar J, Collini P, Shurmer J, Yates B, Baillie JK, Buch MH, Day J, Faust SN, Jaki T, Jeffery K, Juszczak E, Knight M, Lim WS, Montgomery A, Mumford A, Rowan K, Thwaites G, Haynes R, Landray MJ. [Dimethyl fumarate in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) **Nat Commun** 2024; 15(1):924.

B74. Santos JV, Padron-Monedero A, Bikbov B, Grad DA, Plass D, Mechili EA, Gazzelloni F, Fischer F, Sulo G, Ngwa CH, Noguer-Zambrano I, Penalvo JL, Haagsma JA, Kissimova-Skarbek K, Monasta L, Ghith N, Sarmiento-Suarez R, Hrzic R, Haneef R, O'Caioimh R, Cuschieri S, Mondello S, Kabir Z, **GBD 2019 EU State of Health Collaborators,** Freitas A, Devleeschauwer B. [The state of health in the European Union \(EU-27\) in 2019: a systematic analysis for the Global Burden of Disease study 2019.](#) **BMC Public Health** 2024; 24(1):1374.

B75. GBD 2021 Demographics Collaborators. [Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2024; 403(10440):1989-2056.

B76. GBD 2021 Causes of Death Collaborators. [Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2024; 403(10440):2100-2132.

B77. GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. [Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021.](#) **Lancet Infectious Diseases** 2024; S1473-3099(24)00176-2.

B78. GBD 2021 Diseases and Injuries Collaborators. [Global incidence, prevalence, years lived with disability \(YLDs\), disability-adjusted life-years \(DALYs\), and healthy life expectancy \(HALE\) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2024; 403(10440):2133-2161.

B79. GBD 2021 Forecasting Collaborators. [Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2024; 403(10440): 2204-2256.

B80. GBD 2021 Risk Factors Collaborators. [Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2024; 403(10440):2162-2203.

B81. Sivapalan P, Rømer V, Wirenfeldt Klausen T, Johansen NT, Pareek M, Modin D, **Mathioudakis AG,** Vestbo J, Eklöf J, Jordan A, Hurst JR, Biering-Sørensen T, Jensen JU. [LAMA By Night Trial: AM/PM dosing compared for COPD via digital recruitment & registries: Study protocol for a randomized controlled trial.](#) **Frontiers in Medicine** 2024. In press.

****B82. Mathioudakis AG,** Bate S, Sivapalan P, Jensen JU, Singh D, Vestbo J. [Rethinking Blood Eosinophils for Assessing ICS Response in COPD: A Post-Hoc Analysis from FLAME.](#) **Chest** 2024; 166(5): 987-997.

B83. Robey RC, Logue C, Caird C, Hansel J, Hellyer TP, Simpson J, Dark P, **Mathioudakis AG,** Felton T. [Immunomodulatory drugs in sepsis: a systematic review and meta-analysis.](#) **Anaesthesia** 2024; 79(8):869-879.

B84. Hansel J, Mannan F, Robey R, Kumarendran M, Blandon S, **Mathioudakis AG,** Ogungbenro K, Dark P, Felton T. [Covariates in population pharmacokinetic studies of critically ill adults receiving beta-lactam antimicrobials: A systematic review and narrative synthesis.](#) **JAC Antimicrob Resist** 2024; 6(1):dlae030.

B85. Pasioti M, Xepapadaki P, **Mathioudakis AG,** Lakoumentas J, Efstathiou E, Papadopoulos NG. [Current options in the management of tree nut allergy. A systematic review and narrative synthesis.](#) **Pediatric Allergy and Immunology.** 2024; 35(5):e14132.

****B86.** Fally M, Haseeb F, Kouta A, Hansel J, Robey RC, Williams T, Welte T, Felton T, **Mathioudakis AG.** [Unravelling the complexity of ventilator-associated pneumonia: A systematic methodological literature review of diagnostic criteria and definitions used in clinical research.](#) **Crit Care** 2024; 28(1):214.

B87. Heerfordt CK, Rønn C, Eklöf J, Sivapalan P, Harboe ZB, Hyldgaard C, Fløe A, **Mathioudakis AG,** Højbjerg Lassen MC, Biering-Sørensen T, Jensen JUS. [Inhaled Corticosteroids Particle Size and Risk of Hospitalization due to Exacerbations and All-cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study.](#) **Int J Chron Obstruct Pulmon Dis** 2024. Accepted for publication.

B88. Khaleva E, Brightling C, Eiwegger T, Altraja A, Begin P, Blumchen K, Bossios A, Bourdin A, Brinke AT, Brusselle G, Bumbacea RS, Bush A, Casale TB, Clarke GW, Chaudhuri R, Chung KF, Coleman C, Corren J, Dahlen SE, Deschildre A, Djukanovic R, Eger K, Exley A, Fleming L, Fowler SJ, Gaillard E, Gappa M, Gupta A, Haitchi HM, Hashimoto S, Heaney LG, Heldin G, Henderson M, Hua W, Jackson DJ, Karadag B, Katelaris CE, Koh MS, Kopp MV, Koppelman GH, Kull I, Kurukulaaratchy RJ, Lee J-H, Mahler V, Makela M, Masoli M, **Mathioudakis AG,** Mazon A, Melen E, Milger K, Moeller A, Murray CS, Nagakumar P, Nair P, Negus J, Nieto A, Papadopoulos NG, Paton J, Pijnenburg MW, Pike KC, Porsbjerg C, Rattu A, Rupani H, Rusconi F, Rutjes NW, Saglani S, Seddon P, Siddiqui S, Singer F, Tajiri T, Turner S, Upham JW, Vijverberg SJH, Wark PAB, Wechsler ME, Yasinska V, Roberts G, on behalf of the 3TR asthma definition of response working group. [Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.](#) **Eur Respir J** 2025;65(3):2400691.

B89. Bonnesen B, Eklöf J, Biering-Sørensen T, Modin D, Miravittles M, **Mathioudakis AG,** Sivapalan P, Jensen

JUS. [Effect of Low Climate Impact vs. High Climate Impact Inhalers for Patients with Asthma and COPD -can we achieve disease control with low climate impact inhalers?](#) **Respir Res** 2024. Accepted for publication.

B90. GBD 2021 Antimicrobial Resistance Collaborators. [Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050.](#) **Lancet** 2024. Accepted for publication.

****B91.** Fally M, Hansel J, Robey R, Haseeb F, Kouta A, Williams T, Felton T, **Mathioudakis AG.** [Decoding community-acquired pneumonia: a systematic methodological literature review and comprehensive analysis of diagnostic criteria and definitions used in clinical trials.](#) **Clinical Microbiology and Infection** 2025. Accepted for publication.

****B92.** Bate S, Fortescue R, Fullwood C, Sperrin M, Simmonds M, Fally M, Hansel J, Miligkos M, Manohar S, Howlett E, Linnell J, Preston A, the ICS-RECODE group, Woodcock AA, Singh D, Stewart LA, Vestbo J, **Mathioudakis AG.** [Predictors of treatment REsponse to inhaled corticosteroids \(ICS\) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation. Protocol of the ICS-RECODE individual participant data meta-analysis.](#) **BMJ Open** 2025. Accepted for publication.

B93. RECOVERY Collaborative Group. [Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) **eClinicalMedicine** 2025; 81:103080.

B94. GBD 2021 HAP Collaborators. [Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.](#) **Lancet** 2025. In press.

B95. GBD 2021 Asthma and Allergic Diseases Collaborators. [Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.](#) **Lancet Respir Med** 2025. In press.

****B96. Mathioudakis AG,** Higham A, Bate S, Chatzimavridou-Grigoriadou V, Sivapalan P, Jensen JUS, Felton T, Vestbo J, Singh D. [Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: Insights from the FLAME trial.](#) **Thorax** 2025. In press. **Associated editorial:** Hamou-Kuipers EB, Couillard S. Smoking gun: when COPD therapies fail current smokers. **Thorax**, 2025.

B97. GBD 2019 Acute and Chronic Care Collaborators. [Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019.](#) **Nat Commun** 2025 May 7;16(1):4235.

B98. RECOVERY Collaborative Group. [Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 \(RECOVERY\): a randomised, controlled, open-label, platform trial.](#) **Lancet Infect Dis** 2025;S1473-3099(25)00093-3.

B99. Chatziantoniou A*, Karagiannis K*, **Mathioudakis AG***, Synolaki E, Apostolou E, Sideras P, Tzanakis N, Siafakas NM, Antoniou KM. [Activin A/follistatin axis in airway diseases and its possible role in predicting future exacerbations.](#) **In vivo** 2025. In press.

Reviews, Editorials, Letters:

C1. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou EI, Mathioudakis GA. [Chronic Bronchitis: An objective diagnosis of exclusion.](#) **Eur Respir J** 2012; 40(5):1305.

C2. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis GA. [Vasoactive Intestinal Peptide Inhaled Agonists: Potential role in Pulmonary Therapeutics.](#) **Hippokratia** 2013; 17(1):12-16.

C3. Mathioudakis AG, Mathioudakis GA. [Tiotropium Inhaler Devices: Seeking convenience when mortality is at stake?](#) **J Aerosol Med Pulm Drug Deliv** 2013; 26(2):120.

C4. Corlateanu A, Montanari G, **Mathioudakis AG,** Botnaru V, Siafakas NM. [Management of stable COPD: An update.](#) **Curr Resp Med Rev** 2013; 9: 352-359.

C5. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Mathioudakis GA, Calverley PMA. [COPD phenotypes and biomarkers: Introducing personalised medicine.](#) **Curr Resp Med Rev** 2013; 9(6):372-378.

C6. Mathioudakis AG. [Current approach to COPD management: Setting a model in medical therapeutics.](#) **Curr Resp Med Rev** 2013; 9(6):350-351.

C7. Chatzimavridou-Grigoriadou V, **Mathioudakis AG,** Corlateanu A, Mathioudakis GA, Evangelopoulou E. [Obstructive Sleep Apnoea and Hypertension: A bidirectional causal relation.](#) **Curr Resp Med Rev** 2015; 11(4):272-277.

C8. Corlateanu A, Botnaru V, **Mathioudakis AG,** Sircu V, Siafakas N. [Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Sleep Apnoea: A two-faced Janus.](#) **Curr Resp Med Rev** 2015; 11(4):308-313.

C9. Mathioudakis AG, Mastoris I, Chatzimavridou-Grigoriadou V, Mathioudakis GA. [The Risk of Tachyarrhythmias in Patients with Moderate-to-Severe Chronic Kidney Disease Receiving Tiotropium Bromide.](#) **Int J Cardiol** 2015; 197:105-106.

C10. Mathioudakis AG, Hardavella G. [From lung cancer screening to targeted therapies: The endless race against lung cancer morbidity and mortality.](#) **J Lung Cancer Diagn Treat** 2016, 1:1.

C11. Jovanovic D, Toma TP, Corlateanu A, Chkhaidze I, **Mathioudakis AG,** Andreeva E, Samarzija M, Ivanov Y, Skrickova J, Hodzhev V. [Towards a regional network of respiratory medicine.](#) **Pneumologia** 2016; 65(1):56.

C12. Corlateanu A, Covantev K, **Mathioudakis AG,** Botnaru V, Siafakas N. [Prevalence and burden of comorbidities in COPD.](#) **Respir Investig** 2016; 54(6):387-396.

C13. Chatzimavridou-Grigoriadou V, Kanavidis P, **Mathioudakis AG.** [Valvular-CHADS-VASc as a safer alternative to CHADS-VASc Score. \(Quality Improvement Project\).](#) **Int J Cardiol** 2016; 221:1051-1052.

C14. Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis GA. [Serum procalcitonin to guide antibiotic administration for respiratory tract infections in primary care.](#) **BMJ** 2016; 354:i4245.

C15. Bos LD, Bartel S, Ojanguren I, Kahn N, **Mathioudakis AG,** Flood E, Petrarca L, Singanayagam A, Hardavella G. [Early Career Members at the ERS International Congress London 2016: Early Career Forum.](#) **Breathe (Sheff)** 2016; 12 (4) 364-368.

C16. Corlateanu A, Covantev K, **Mathioudakis AG,** Botnaru V. [Anemia in COPD.](#) **Pneumologia** 2016; 65(3):168.

C17. Mathioudakis AG, Rousalova I, Aamli Gagnat A, Saad N, Hardavella G. [How to keep good clinical records?](#) **Breathe (Sheff)** 2016; 12 (4) 369-373.

- C18.** Bos LD, Bartel S, **Mathioudakis AG**, Flood E. Opportunities for early career members. *Breathe (Sheff)* 2017; 13(2):127-8.
- C19.** Guibas GV, **Mathioudakis AG**, Tsoumani M, Tsaouri S. Allergy and asthma: Chicken and the egg? *Front Pediatr* 2017; 5:92.
- C20.** **Mathioudakis AG**, Equiluz Garcia, Bartel S, Tsilochristou O. ERS Early Career Members meet FAACT Junior Members: The launch of a strong, fruitful collaboration. *Breathe (Sheff)* 2017; 13(3):231-3.
- C21.** Normansell R, Kew K, Stovold E, **Mathioudakis AG**, Dennett E. Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma. *Paediatr Respir Rev* 2017; 23:53-5.
- C22.** **Mathioudakis AG**, Satia I, Adcock IM. Airways diseases: Insights from the European Respiratory Society Annual Congress 2017. *J Thorac Dis* 2017;9(Suppl 16):S1550-S1553.
- C23.** Andersson C, Bonvini S, Horvath P, Marquez E, Satia I, Kirkham P, Schleich F, Idzko M, Gosens R, Lopez-Campos JL, Bossios A, Usmani O, Spanevello A, Adcock IM, **Mathioudakis AG**. Research Highlights from the 2017 European Respiratory Society International Congress: Airway Diseases in Focus. *ERJ Open Res* 2018;4(1). pii: 00163-2017.
- C24.** **Mathioudakis AG**. Capsule Commentary on Bremner et. Al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations. *J Gen Intern Med* 2018;33(5):749.
- C25.** Corlateanu A, Covantev S, **Mathioudakis AG**, Botnaru V, Cazzola M, Siafakas N. Chronic obstructive pulmonary disease and stroke. *COPD* 2018; 15(4):405-413.
- C26.** Siafakas N, Bizymi N, **Mathioudakis AG**, Corlateanu A. Early versus mild chronic obstructive pulmonary disease (COPD). *Respir Med* 2018; 140: 127-131.
- C27.** Mastoris I, **Mathioudakis AG**. Capsule Commentary on Ashburner et. al., Electronic physician notifications to improve guideline-based anticoagulation in atrial fibrillation: a randomized controlled trial. *J Gen Intern Med* 2018; 33(12):2190.
- **C28.** Vestbo J, **Mathioudakis AG**. The emerging Chinese COPD epidemic. *Lancet* 2018; 391(10131):1642-1643.
- C29.** **Mathioudakis AG**, Vestbo J. Was the implementation strategy of the ProACT trial adequately proactive? *Breathe (Sheff)* 2019; 15(1):77-80.
- C30.** Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA; on behalf of the CADSET Clinical Research Collaboration; **Current members of the CADSET Clinical Research Collaboration.** Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. *Eur Respir J* 2019; 53(3):1900217.
- C31.** Schleich F, Bikov A, **Mathioudakis AG**, McDonnell M, Andersson C, Bonini M, Uller L, Idzko M, Singh D, Lopez-Campos JL, Bossios A, Adcock IM, Usmani O, Spanevello A, Bonvini SJ. Research highlights from the 2018 European Respiratory Society International Congress: airway disease. *ERJ Open Res* 2019; 5:00225-2018
- C32.** Lahousse L, Bahmer T, Cuevas-Ocana S, Flajolet P, **Mathioudakis AG**, McDonnell M, Uller L, Schleich F, Dortas S Jr, Idzko M, Singh D, Ricciardolo FLM, Adcock IM, Usmani O, Spanevello A, Bonvini SJ. ERS International congress, Madrid 2019: Highlights from the Airway Disease, Asthma and COPD Assembly. *ERJ Open Res* 2020; 6(1):00341-2019.
- **C33.** Equiluz-Gracia I*, **Mathioudakis AG*(shared first authorship)**, Bartel S, Vijverberg SJH, Fuertes E, Comberiat P, Cai YS, Tomazic PV, Diamant Z, Vestbo J, Galan C, Hoffmann B. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. *Allergy* 2020;75(9):2170-2184.
- **C34.** **Mathioudakis AG**, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JU, Vestbo J. Acute exacerbations of chronic obstructive pulmonary disease: In search of diagnostic biomarkers and treatable traits. *Thorax* 2020; 75(6):520-527.
- **C35.** **Mathioudakis AG**, Sivapalan P, Papi A. Vestbo J, on behalf of the DECODE-NET (DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETWORK). The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETWORK: DECODE-NET. Rationale and vision. *Eur Respir J* 2020; 56(1):2000627.
- C36.** **Mathioudakis AG**, Vanfleteren LEGW, Lahousse L, Higham A, Allinson JP, Gotera C, Visca D, Singh D, Spanevello A. Current developments and future directions in COPD. *Eur Respir Rev* 2020; 29(158):200289.
- C37.** Higham A, **Mathioudakis AG**, Vestbo J, Singh D. COVID-19 and COPD: A narrative review of the basic science and clinical outcomes. *Eur Respir Rev* 2020; 29(158):200199.
- C38.** **Mathioudakis AG**, Vestbo J, Singh D. Long-acting bronchodilators for chronic obstructive pulmonary disease. Which one(s), how, and when? *Clin Chest Med* 2020; 41(3): 363-374.
- C39.** **Mathioudakis AG**, Fally M, Hashad R, Knight S, Felton T, Vestbo J. COVID-19 clinical trials: Unravelling a methodological Gordian knot. *Am J Respir Crit Care Med* 2020; 202(5):635-637.
- C40.** Ulinici M, Covantev S, Wingfield-Digby J, Beloukas A, **Mathioudakis AG**, Corlateanu A. Screening, Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review. *Life* 2021; 11(6):561.
- C41.** Corlateanu A, Plahotniuc A, Corlateanu O, Botnaru V, Bikov A, **Mathioudakis AG**, Covantev S, Siafakas N. Multidimensional indices in the assessment of chronic obstructive pulmonary disease. *Respir Med* 2021; 185:106519.
- **C42.** **Mathioudakis AG**, Ananth S, Vestbo J. Stigma: An unmet public health priority in COPD. *Lancet Respir Med* 2021; 9(9):955-956.
- C43.** Singh D, Lea S, **Mathioudakis AG**. Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease. *Drugs* 2021; 81(16):1821-1830.
- C44.** Bonnesen Bertelsen B, Jensen JUS, Jeschke KN, **Mathioudakis AG**, Corlateanu A, Frausing Hansen E, Møller Weinreich U, Hilberg O, Sivapalan P. Management of COVID-19 Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation. *Diagnostics* 2021; 11(12):2259.
- C45.** Singh D, **Mathioudakis AG**, Higham A. Chronic obstructive pulmonary disease and COVID-19: interrelationships. *Curr Opin Pulm Med* 2022; 28(2):76-83.
- C46.** **Mathioudakis AG**, Osadnik C, Boots AW, Bradicich M, Bartel S, Gloeckl R, Cruz J. Inspiring stories: the impact that being part of ERS activities can have on a professional career. *Breathe (Sheff)* 2022; 18(1):210217.

- C47.** Odajiu I, Covantsev S, Sivapalan P, **Mathioudakis AG**, Jensen JUS, Davidescu EI, Chatzimavridou-Grigoriadou V, Corlateanu A. Peripheral neuropathy: A neglected cause of disability in COPD – a narrative review. **Respir Med** 2022; 201:106952.
- C48. Mathioudakis AG**, Wagner D, Dumas O. How to peer review? Practical advice for early career researchers. **Breathe (Sheff)** 2022; 18(4):220160.
- C49.** Stolz D, Matera MG, Rogliani P, van den Berge M, Papakonstantinou E, Gosens, R, Singh D, Hanania N, Cazzola M, Maitland-van der Zee AH, Fregonese L, **Mathioudakis AG**, Vestbo J, Rukhadze M, Page C. Pharmacology of asthma and COPD: Current and future developments. **ERS Seminar, Naples 2022**. **Breathe (Sheff)** 2023; 19(2):220267.
- C50.** Beech A, Portacci A, Herrero-Cortina B, **Mathioudakis AG**, Gotera C, Uller L, Ricciardolo FLM, Pobeha P, Snelgrove RJ, Braunstahl GJ, Bossios A, Usmani O, Ananth S. Research highlights from the 2022 European Respiratory Society International Congress: Airway Diseases. **ERJ Open Res** 2023; 9(3):00034-2023.
- C51.** Soumagne T, Zysman M, Karadogan D, Lahousse L, **Mathioudakis AG**. Impact of triple therapy on mortality in COPD. **Breathe (Sheff)** 2023; 19(1):220260.
- C52.** Out A, Kosmidis C, **Mathioudakis AG**, Ibe C, Denning D. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease. **Infection** 2023; 51(4):813-829.
- C53.** Bergantini L, Baker J, Bossios A, Braunstahl G-J, Conemans LH, Lombardi F, **Mathioudakis AG**, Pobeha P, Ricciardolo FLM, Romero LPP, Schleich F, Snelgrove RJ, Trinkmann F, Uller L, Beech A. ERS International Congress 2023: highlights from the Airway Diseases Assembly. **ERJ Open Res** 2023; 10(2):00891-2023.
- **C54. Mathioudakis AG**, Khaleva E, Fally M, Williamson PR, Jensen JU, Felton TW, Brightling C, Bush A, Winders T, Linnell J, Ramiconi V, Coleman C, Welte T, Roberts G, Vestbo J. Core outcome sets developed collaboratively with patients, can improve the relevance and comparability of clinical trials. **Eur Respir J** 2023; 61(4):2202107.
- C55.** Calaras D, **Mathioudakis AG**, Lazar Z, Corlateanu A. Combined pulmonary fibrosis and emphysema: comparative evidence on a complex condition. **Biomedicines** 2023; 11(6):1636.
- C56.** Bonnesen Bertelsen B, Jensen JUS, **Mathioudakis AG**, Corlateanu A, Sivapalan P. Promising treatment biomarkers in asthma. **Front Drug Saf Regul** 2023; 3:1291471.
- C57.** Bennett MR, **Mathioudakis AG**, Tontini C, Simpson A. Reply to "The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy". **JACI: In Practice** 2024; 12(3):802-3.
- C58.** Ananth S, **Mathioudakis AG**, Hansel J. Steroids in severe community-acquired pneumonia. **Breathe** 2024. In press.
- C59.** Lim CX, Abohalaka R, Wang R, Sykes DL, Ardesi F, Zappa M, Bonini M, Braunstahl G-J, **Mathioudakis AG**, Snelgrove RJ, Pobeha P, Ananth S, Schleich F, Bossios A, Beech A. European Respiratory Society International Congress 2024: Highlights from Assembly 5 – Airway diseases. **ERJ Open Res** 2025. Accepted for publication.
- C60.** Singh D, Higham A, **Mathioudakis AG**, Beech A. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments. **Drugs** 2025. In press.
- C61. Mathioudakis AG**, Souto-Miranda S. Beyond survival: Improving lung cancer rehabilitation through standardised outcomes. **ERJ Open Res** 2025. In press.
- C62.** Jensen JUS, Johansen ND, **Mathioudakis AG**, Biering-Sørensen T, Sivapalan P. The silent exclusion - Rethinking eligibility and generalizability in clinical trials. **Lancet Reg Health West Pac** 2025. In press.

Projects

Grants held:

- Principal Investigator, National Institute for Health and Care Research Health Technology Assessment (NIHR HTA). NIHR152516 - ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in COPD: randomised COntrolled trials individual participant Data re-Evaluation. 2023.
- Co-investigator, European Centre for Disease Prevention and Control (ECDC). OJ/2022/PHF/24511: Literature reviews on topics related to public health emergency preparedness and response. 2023.
- Co-investigator, NIHR Manchester Biomedical Research Centre (BRC) Next Generation Therapeutics Theme Pump priming project call. AccReDIT platform diagnostics: Infection and immune phenotypes and treatable traits assessment. 2023.
- Co-investigator, NIHR Biomedical Research Centres Programme. NIHR Manchester Biomedical Research Centre (BRC). 2022
- Co-principal investigator, Boehringer Ingelheim Investigator Initiated Grant. Characterisation and targeted Treatment of ACute Exacerbations of COPD (the TRACE-COPD trial). 2017
- Co-investigator. North West Lung Centre Charity Research Grant. 2017.

Main research projects:

- I led independent post-hoc analyses of COPD therapeutic trials that revealed novel precision medicine signals. Notably, I demonstrated that change in blood eosinophil count on ICS treatment is a more accurate biomarker of ICS response, further validated the hypothesis that current smokers gain less benefit from ICS, and elucidated the real-world impact of ICS and LAMA withdrawal effects amid suboptimal treatment adherence (Mathioudakis et al, ERJ 2020; Mathioudakis et al, Chest 2024). Building on these insights, I am now conducting an individual participant data meta-analysis of over 60,000 randomised participants to further refine predictors and develop predictive models of ICS treatment response in COPD.
- I led the development of the ERS COPD exacerbations core outcome set, that was based on rigorous systematic reviews and a globally representative, multistakeholder consensus (Mathioudakis et al, ERJ 2022). This has been endorsed by 4 international societies and promotes quality and consistency in the selection of outcomes in COPD exacerbations trials.
- I have led or contributed to >40 evidence syntheses, including complex methodologies, to address clinically relevant questions around phenotyping and therapeutics (including personalised approaches) of airway diseases and respiratory infections.
- I contributed to the design and analysis/interpretation of the LAMA-by-night trial, an innovative RCT that used routinely collected patient data to identify and recruit >10k participants and monitor their outcomes without missingness.

- I have contributed to the development of GRADE methodology for evidence syntheses and development of clinical practice guidelines.

Investigator/ Co-investigator in multi-centre studies

- Global Burden of Disease (GBD) study. Senior Collaborator. 2024-now (Collaborator: 2022-2024)
- PeARL (Pediatric Asthma in Real Life). Steering Committee Member. 2019-2024.
- NOVELTY Study. PI for Manchester University NHS Foundation Trust. 2019-2024.
- TRACE-COPD. Co-CI & PI for Manchester University NHS Foundation Trust. 2018-2022.
- GRADE Working Group. Collaborator. 2016-now.
- Investigator (study delivery): AcCreDiT, Early COPD Cohort, RADICA, RECOVERY, ACCORD-2, CHINOOK, Tilia, INPULSIS-2.

Memberships

Main Scientific Awards and Honors

- 2025: Elected Fellow of the European Respiratory Society (FERS). Awarded to 14 members worldwide in 2025 for outstanding clinical and/or research leadership.
- 2023, 2024: Included in the Stanford University-Elsevier lists of top 2% Scientists globally
- 2022: European Respiratory Society Early Career Member Award 2022.
- 2022: Mina Gaga Lecture, European Respiratory Society Congress, 2022.
- 2012: Charles W. Serby COPD Research Fellowship, American Respiratory Care Foundation.

Personal Research Fellowships

- 2025: Pickering Fellowship, North West Lung Charity
- 2022: National Institute for Health and Care Research (NIHR) Academic Clinical Lectureship in Respiratory Medicine
- 2018: NIHR Manchester Biomedical Research Centre (BRC) PhD studentship.
- 2016: NIHR Academic Clinical Fellowship in Respiratory Medicine
- 2016: European Respiratory Society (ERS) Guidelines Methodology Fellowship.

I hold/ have held leadership positions at National and International Societies

- Member of the Advocacy Council of the European Respiratory Society (ERS, 2025-2028).
- Member of the ERS Guidelines Working Group (2025-2028)
- Co-Chair of an European Respiratory Society (ERS) Task Force aiming to develop a core outcome set for clinical research on the management of chronic obstructive pulmonary disease (2025-2027).
- Chair of Group 5.1 - Airway Pharmacology and treatment (2024-2027)
- Panel member of the COMPAR-EU panel developing clinical recommendations for self-management in COPD (EU funded project, 2021-).
- Panel Member and Methodologist of an ERS Task Force aiming to develop a Core Outcome Set for the management of pneumonia (2021-2025, in submission).
- Early Career co-chair of the DisEntangling Chronic Obstructive pulmonary Disease Exacerbations: An international clinical trials NETWORK (the DECODE-NET, since 2019).
- Member of the ERS College of Experts (since 2017).
- Secretary of the European Respiratory Society (ERS) Group 5.1 - Airway Pharmacology and treatment (2021-2024).
- Panel Member and Methodologist of an ERS Task Force aiming to develop Clinical Practice Guidelines on the Diagnosis and Management of Pulmonary Alveolar Proteinosis (2021-2024).
- Member of the Steering Committee of the Pediatric Asthma in Real Life (PeARL) think tank (2019-2024).
- Member of the European Respiratory Society Clinical Research Collaboration CADSET (2018-2021).
- Co-Chair of an ERS Task Force aiming to develop a core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease (2019-2021).
- Member of the British Thoracic Society (BTS) Standards of Care Committee (2017-2021).
- Co-Chair of ERS / European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Management of Asthma. (2016 – 2021).
- Member of the ERS Sarcoidosis Treatment Guideline Methodology Group (2016-2021).
- Member of the Health Research Authority - Research Ethics Committee North Western (2018-2020).
- Member of the Guidelines panel of the BTS/SIGN Asthma Guidelines (2017-2019).
- Member of the ERS Guidelines Working Group (2016 – 2019).
- Member of Early Career Members Committee (ECMC) of ERS, Representing Assembly 5 (Airway Diseases, 2016-2019).
- Coordinator of ERS - EAACI Early Career Members Committees Collaboration. (2015-2019)
- Appointed Representative of the Junior Members of ERS Group 5.1. (2015-2016)

- Appointed Representative of the Junior Members of ERS Assembly 5 and contributed to the development of ERS Early Career Members Committee. (2012-2013)

- Elected Member of the Council of the Medical Students of Athens' Union. Representative of the Union in the Medical School of Athens' Academic Council. Member of the Medical School of Athens' Curriculum Reform Board, September 2008 – August 2011 (Annual duty, Elected 3 consecutive times).

Editorial Board Memberships

- Editor, Cochrane Database of Systematic Reviews (Cochrane Airways, 2019-now).
- Section Editor, Journal Club Section, Breathe, The Official ERS Educational Journal (2020-now)
- Associate Editor, Asthma Research and Practice (2022-2023)
- Associate Editor, Frontiers in Drug Safety and Regulation (2021-now)
- Academic Editor, Disease Markers (Hindawi, 2020-2022)
- Associate Editor, Frontiers in Allergy (2024-now)
- Section Editor, Folia Medica (2016-2020)
- Editor, Pneumologia (The official journal of the Romanian Society of Pneumology, 2023-now)
- Guest Academic Editor, PLOS Medicine (2025-now)
- Guest Editor, Biomedicines (2022)
- Member of the Editorial Board in Respiratory Research (Biomed Central, 2025), Therapeutic Advances in Respiratory Disease (Sage, 2024), Pulmonary Therapy (Springer, 2022), Advanced in Respiratory Medicine (MDPI, 2022), Population Medicine (2022), Frontiers in Allergy (2021-2024), Frontiers in Virology (2021-2024) and Archives of Hellenic Medicine (2014).

Society / Network Memberships

- General Medical Council UK - Full registration (7254412)
- Royal College of Physicians of London - MRCP(UK, Respiratory)
- British Thoracic Society
- British Medical Association
- European Respiratory Society
- American Thoracic Society
- Hellenic Thoracic Society
- Central and Eastern Europe Respiratory Network
- European Academy of Allergy and Clinical Immunology
- Cochrane
- GRADE Working Group (Grading of Recommendation Assessment, Development and Evaluation).
- Global Burden of Disease Collaborator Network.
- Hellenic Society for the Advancement of Biomedical Research (Board Member since 2008)
- Athens Medical Association (Greece).

Other Relevant Information